DGAP-News: Evotec achieves first milestones in multi-target deal with UCB
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Miscellaneous
Evotec achieves first milestones in multi-target deal with UCB
28.10.2013 / 07:30
---------------------------------------------------------------------
Hamburg, Germany - 28 October 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that it has achieved first
milestones in its multi-year, multi-target integrated drug discovery
collaboration with UCB in the field of immunology.
The milestones were achieved upon the progression of certain projects into
hit-to-lead and into lead optimisation.
Evotec and UCB entered into this collaboration in October 2011. Under the
terms of the collaboration, Evotec receives research payments, milestones
based on achieving various pre-clinical, clinical and sales goals and
royalties on final product sales.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: 'We are
delighted that the project teams at UCB and Evotec have met these important
milestones in the collaboration. The progress in this collaboration is a
testament to the way scientists from both companies have worked together in
a true partnership.'
Dr Neil Weir, Senior Vice President of Discovery at UCB, commented that
'The collaboration with Evotec complements our internal research efforts
and enhances our scientific network. Hitting these milestones is great news
and as we continue to work together, we hope that the results will enhance
the pace of the discovery process, the quality of compounds selected for
further development and ultimately improve patient outcomes.'
No financial details were disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Ono Pharmaceutical and UCB. In addition, the Company has existing
development partnerships and product candidates both in clinical and
pre-clinical development. These include partnerships with Boehringer
Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with
Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and
solutions to transform the lives of people living with severe diseases of
the immune system or of the central nervous system. With more than 9000
people in about 40 countries, the company generated revenue of EUR 3.4
billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
FORWARD-LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involvea number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
28.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
236370 28.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 309651
Anzahl Zeichen: 4355
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec achieves first milestones in multi-target deal with UCB"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
